Clinical trials: Hospitalized Patient
Colonoscopy
The Affect of Low-Volume Bowel Preparation for Hospitalized Patients Colonoscopies
The purpose of this study is to compare the efficacy of a low-volume bowel preparation versus a high-volume bowel preparation for bowel cleansing on hospitalized patients undergoing colonoscopies.
- Trial name
- NCT01978509
- Testing
- Low volume prep (Prepopik), Moderate volume prep (Moviprep), High volume prep (Golytely)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Coronavirus, COVID
A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
This was a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care (SOC), compared with placebo plus SOC, in participants with respiratory signs and…
- Conditions
- Coronavirus, COVID, ARDS, Cytokine Storm
- Trial name
- NCT04415073
- Testing
- SNDX-6352
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Syndax Pharmaceuticals
Alzheimer Disease, Dementia
Aligning Patient Preferences: a Role Offering Alzheimer's Patients, Caregivers, and Healthcare Providers Education and Support
Nursing home (NH) patients with Alzheimer's disease and related dementias often receive unwanted, burdensome treatments such as hospitalization.
- Trial name
- APPROACHES (NCT03323502)
- Testing
- APPROACHES ACP Specialist Program, Standard of care
- Where
- 2 sites in United States
- Volunteers
- 47,396 people
- Sponsor
- Indiana University
Corona Virus Infection, Acute Respiratory Distress Syndrome
Losartan for Patients With COVID-19 Not Requiring Hospitalization
This is a multi-center, double-blinded study of COVID-19 infected patients randomized 1:1 to daily losartan or placebo for 10 days or treatment failure (hospital admission).
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
- Trial name
- NCT04311177
- Testing
- Losartan
- Where
- 4 sites in United States
- Volunteers
- 117 people
- Sponsor
- University of Minnesota
Virus Diseases
Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza
Danirixin (DNX) is a novel, selective, and reversible antagonist of the C-X-C chemokine receptor (CXCR) 2 and has been shown to decrease neutrophil transmigration and activation to areas of inflammation.
- Trial name
- NCT02927431
- Testing
- Danirixin 15 mg FBE, Danirixin 50 mg FBE, Oseltamivir 75 mg
- Where
- 8 sites in United States, Romania and 2 more
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
COVID-19
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19
The primary objectives are: Pooled Phase 3 (Cohort 1) and Phase 2 (Cohort 1A) To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2 To evaluate the clinical efficacy of…
- Trial name
- NCT04426695
- Testing
- REGN10933+REGN10987 combination therapy
- Where
- 123 sites in United States, Brazil and 4 more
- Volunteers
- 2,252 people
- Sponsor
- Regeneron Pharmaceuticals
Covid19
VIR-7831 for the Early Treatment of COVID-19 in Outpatients
This is a phase 2/3 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 or placebo and will be assessed for safety, tolerability, efficacy, and pharmacokinetics.
- Trial name
- COMET-ICE (NCT04545060)
- Testing
- VIR-7831 (sotrovimab)
- Where
- 91 sites in United States, Austria and 5 more
- Volunteers
- 1,057 people
- Sponsor
- Vir Biotechnology, Inc.
COVID
Maraviroc in Patients With Moderate and Severe COVID-19
Maraviroc, a C-C Chemokine Receptor 5 (CCR5) antagonist, is well-tolerated without significant side effects in its current use in patients with HIV.
- Trial name
- NCT04435522
- Testing
- Maraviroc
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Rhode Island Hospital
Pulmonary Disease, Chronic Obstructive
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2
A randomized, placebo-controlled, double-blind, parallel group, multi-center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT01662986
- Testing
- tiotropium bromide
- Where
- 50 sites in United States
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Chronic Heart Failure
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure
The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure…
- Trial name
- ATMOSPHERE (NCT00853658)
- Testing
- Enalapril, Aliskiren
- Where
- 806 sites in United States, Argentina and 42 more
- Volunteers
- 7,064 people
- Sponsor
- Novartis Pharmaceuticals
Infections, Coronavirus
Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19
The study is designed as an open observational non-comparative study of Polyoxidonium®, lyophilizate for solution for injections and topical application, 12 mg in hospitalized patients with coronavirus disease (COVID-19).
- Trial name
- NCT04542226
- Testing
- Polyoxidonium
- Where
- 5 sites in Belarus, Russia
- Volunteers
- 81 people
- Sponsor
- NPO Petrovax
Atrial Fibrillation, Atrial Flutter
A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation
To assess the efficacy of dronedarone in preventing cardiovascular hospitalization or death from any cause in a population of high-risk patients with atrial fibrillation/atrial flutter (AF/AFL).
- Trial name
- ATHENA (NCT00174785)
- Testing
- dronedarone (SR33589)
- Where
- 37 sites in United States, Argentina and 35 more
- Volunteers
- 4,628 people
- Sponsor
- Sanofi
Influenza, Human
A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection
This study will be an open-label, multi-center, single arm study to evaluate the safety and efficacy of IV zanamivir 600mg twice daily for 5 days in hospitalized subjects with laboratory confirmed influenza infection.
- Trial name
- NCT01527110
- Testing
- Intravenous (IV) zanamivir
- Where
- 7 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
COVID-19 Infection
Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
Treatment of patients hospitalised for management of moderate COVID-19 infection
- Trial name
- Neptuno (NCT04784559)
- Testing
- Plitidepsin, Dexamethasone, Remdesivir
- Where
- 28 sites in Brazil, Bulgaria and 6 more
- Volunteers
- 205 people
- Sponsor
- PharmaMar
Covid19
Vaccination for Recovered Inpatients With COVID-19 (VATICO)
In this Phase 4, open-label trial, participants of the ACTIV-3/TICO clinical trial at selected sites who received certain pre-specified blinded investigational agents or placebo as part of that trial, and who have since achieved…
- Trial name
- NCT04969250
- Testing
- Moderna mRNA-1273 COVID-19 vaccine, Pfizer BNT162b2 COVID-19 vaccine
- Where
- 30 sites in United States, Nigeria and 4 more
- Volunteers
- 66 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Schizophrenia, Schizophrenia; Psychosis
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)
This is a Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter inpatient study to examine the efficacy and safety of KarXT in adult subjects who are acutely psychotic with a Diagnostic and…
- Trial name
- NCT04738123
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 32 sites in United States, Ukraine
- Volunteers
- 256 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
COVID-19
COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.
The purpose of this study is to see if this plasma can be safely used in humans with COVID-19 and to see if it improves patients' health as compared to not using it in patients with pneumonia caused by SARS-CoV-2.
- Trial name
- NCT04397757
- Testing
- COVID-19 Convalescent Plasma
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Pennsylvania
Tobacco Smoking, Psychiatric Disorder
Acceptance and Commitment Therapy for Tobacco Cessation Among Psychiatric Partial Hospital Patients
People with serious mental illness are three times more likely to smoke cigarettes than people without mental illness. People with mental illness are less likely to be successful in quitting smoking than those without mental…
- Conditions
- Tobacco Smoking, Psychiatric Disorder, Psychiatric Hospitalization
- Trial name
- NCT03911960
- Testing
- Acceptance and Commitment Therapy, Enhanced Usual Care
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- The Miriam Hospital
Early Mobility, Older Adults
Improving Patient Walking During Hospitalization
The MOVIN (Mobilizing Older adult patients Via a systems-based Intervention) randomized controlled trial is designed to evaluate the impact of the MOVIN intervention on improving the functional ability of older adult hospital…
- Conditions
- Early Mobility, Older Adults, Hospital Acquired Condition
- Trial name
- NCT04479943
- Testing
- MOVIN, Surveys and Focus groups
- Where
- United States
- Volunteers
- 765 people
- Sponsor
- University of Wisconsin, Madison
Complicated Intra-Abdominal Infection
Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections
The objective of this study is to estimate the costs of empiric antibiotic therapy and hospitalization costs for patients with a complicated intra-abdominal infection, and to assess the impact of treatment failure of initial…
- Trial name
- NCT00929643
- Testing
- no intervention
- Where
- 13 sites in Greece
- Volunteers
- 203 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer